1. Scrip
  2. >>Business
  3. >>Financing

Timing Is Everything As Mereo Still Eyes US Listing

 
• By Kevin Grogan

The London-headquartered firm believes that its efficient control of costs and strong data in support of its investigational treatments for rare respiratory, bone and endocrine diseases will attract investors across the Atlantic once it decides to refile for a listing on the Nasdaq.

NASDAQ
Mereo paving road to Wall Street • Source: Shutterstock

The UK's Mereo BioPharma Group PLC is still very keen to get onto the Nasdaq, despite having postponed plans for a listing in April as it claims to be making strong progress on all fronts with its four-product portfolio, each of which was acquired from big pharma.

Speaking to Scrip after giving a six-month update to investors, CEO Denise Scots-Knight said that a potential offering and additional listing of American Depositary Shares on the Nasdaq (Mereo already...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.